What is Utak?
UTAK is a specialized provider of handcrafted Quality Controls (QC) utilizing 100% real human matrices. The company serves clinical and toxicology laboratories, focusing on reducing risks and costs associated with quality assurance. With over five decades of experience, UTAK operates as an independent QC partner, ensuring clients receive compliant and audit-ready quality solutions without the burden of in-house manufacturing complexities. Their offerings include custom QC formulations, rapid manufacturing processes, and comprehensive documentation to guarantee product stability and regulatory adherence. Leading reference laboratories rely on UTAK for cost certainty and dependable quality control.
How much funding has Utak raised?
Utak has raised a total of $446K across 2 funding rounds:
Debt
$150K
Debt
$296K
Debt (2020): $150K with participation from PPP
Debt (2021): $296K led by PPP
What's next for Utak?
The substantial capital infusion, particularly the recent strategic investment, positions UTAK for accelerated expansion and enhanced service delivery. This late-stage funding suggests a focus on scaling production capabilities, broadening market reach, and potentially investing in further technological advancements for their QC solutions. UTAK is poised to solidify its role as a critical partner for laboratories seeking to optimize their quality control processes and ensure regulatory compliance in an increasingly complex healthcare landscape.
See full Utak company page
